Placebo Effect or Just Bad News? Omeros Down On OMS721 IgA Nephropathy Data

 
• By Sten Stovall

Investors and analysts hope Omeros Corp can explain – and soon - why its candidate drug for treating renal diseases performed only slightly better than placebo in tests on IgA nephropathy patients with high risk of progression, sending the biotech's shares sliding.

Kidney
Omeros Jarred Investors With Mixed Results In Its Phase II IgAN Study • Source: Shutterstock

More from Clinical Trials

More from R&D